Pioglitazone versus sulfonylureas: cardiovascular outcomes with older diabetes drugs

Affiliations

¹ Tulane University Health Sciences Center, New Orleans, LA 70112, USA; Southeast Louisiana Veterans Health Care Systems, New Orleans, LA, USA.
² Tulane University Health Sciences Center, New Orleans, LA 70112, USA; Southeast Louisiana Veterans Health Care Systems, New Orleans, LA, USA. Electronic address: dlovre@tulane.edu.

Comment

Vivian A Fonseca et al. Lancet Diabetes Endocrinol. 2017 Nov.

. 2017 Nov;5(11):845-847.

doi: 10.1016/S2213-8587(17)30320-0. Epub 2017 Sep 13.

¹ Tulane University Health Sciences Center, New Orleans, LA 70112, USA; Southeast Louisiana Veterans Health Care Systems, New Orleans, LA, USA.
² Tulane University Health Sciences Center, New Orleans, LA 70112, USA; Southeast Louisiana Veterans Health Care Systems, New Orleans, LA, USA. Electronic address: dlovre@tulane.edu.

No abstract available

Comment on

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society. Vaccaro O, et al. Lancet Diabetes Endocrinol. 2017 Nov;5(11):887-897. doi: 10.1016/S2213-8587(17)30317-0. Epub 2017 Sep 13. Lancet Diabetes Endocrinol. 2017. PMID: 28917544 Clinical Trial.

1. Standards of Medical Care in Diabetes 2017: summary of revisions. Diabetes Care. 2017;40(suppl 1):S4–5. No authors listed. - PubMed
1. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary. Endocr Pract. 2017;23:207–38. - PubMed
1. Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA) Diab Vasc Dis Res. 2015;12:164–74. - PMC - PubMed
1. Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE) Diabetes Care. 2013;36:2254–61. - PMC - PubMed
1. Vaccaro O, Masulli M, Nicolucci A, et al. for the Thiazolidinediones Or Sulphonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017 published online Sept 13. http://dx.doi.org/10.1016/S2213-8587(17)30317-0. - DOI - PubMed